FDA bans use of Lilly, Regeneron COVID drugs due to OmicronThe FDA has limited the use of COVID-19 antibody therapies developed by Eli Lilly and Regeneron, on the Share XFDA bans use of Lilly, Regeneron COVID drugs due to Omicronhttps://pharmaphorum.com/news/fda-bans-use-of-lilly-regeneron-covid-drugs-due-to-omicron/
PolyPhotonix raises $10m to trial sleep mask for diabetic eye diseaseThe UK company behind a sleep mask that aims to treat sight-robbing complications of diabetes has secured $10 Share XPolyPhotonix raises $10m to trial sleep mask for diabetic eye diseasehttps://pharmaphorum.com/news/polyphotonix-raises-10m-to-trial-sleep-mask-for-diabetic-eye-disease/
FDA stifles Merck’s cough drug gefapixant, asking for more dataThe FDA has issued a complete response letter (CRL) to Merck & Co’s gefapixant candidate for refractory chronic Share XFDA stifles Merck’s cough drug gefapixant, asking for more datahttps://pharmaphorum.com/news/fda-stifles-mercks-cough-drug-gefapixant-asking-for-more-data/
Understanding the prevention and treatment needs for cardiovascular diseaseWhat does the current picture of cardiovascular disease in Europe look like? Surprisingly for many, cardiovascular disease (CVD) Share XUnderstanding the prevention and treatment needs for cardiovascular diseasehttps://deep-dive.pharmaphorum.com/magazine/digital-health-2021/interview-with-benoit-creveau-head-of-commercial-operations-specialty-medicines-at-daiichi-sankyo-europe/
Chronic kidney disease: treating a silent killerIn November, NICE backed NHS use of AstraZeneca’s diabetes and heart failure drug Forxiga for the treatment of Share XChronic kidney disease: treating a silent killerhttps://pharmaphorum.com/patients/chronic-kidney-disease-treating-a-silent-killer/
Oslo Medicines Initiative asks how to balance innovation incentivisation with security of accessAccess to medicines is “one of the most challenging policy areas in every country in the European region” Share XOslo Medicines Initiative asks how to balance innovation incentivisation with security of accesshttps://pharmaphorum.com/views-analysis-market-access/oslo-medicines-initiative-balance-innovation-incentivisation-with-security-of-access/
Understanding the prevention and treatment needs for cardiovascular diseaseWhat does the current picture of cardiovascular disease in Europe look like? Surprisingly for many, cardiovascular disease (CVD) Share XUnderstanding the prevention and treatment needs for cardiovascular diseasehttps://deep-dive.pharmaphorum.com/magazine/digital-health-2021/interview-with-benoit-creveau-head-of-commercial-operations-specialty-medicines-at-daiichi-sankyo-europe/
The rise, acceleration and acceptance of telehealth adoption‘Healing at a distance’ is the literal meaning of telemedicine. According to the World Health Organization, it is Share XThe rise, acceleration and acceptance of telehealth adoptionhttps://deep-dive.pharmaphorum.com/magazine/digital-health-2021/the-rise-acceleration-and-acceptance-of-telehealth-adoption/
Targeted agents and immunotherapiesTargeted agents and immunotherapies are two of the most promising areas for significant advancements in cancer treatment. Envision Share XTargeted agents and immunotherapieshttps://deep-dive.pharmaphorum.com/magazine/digital-health-2021/targeted-agents-and-immunotherapies/
Life sciences predictions for 2022 Share XLife sciences predictions for 2022https://pharmaphorum.com/webinars/life-sciences-predictions-for-2022/
Oncology treatment decisions aren’t just based on clinical data Share XOncology treatment decisions aren’t just based on clinical datahttps://pharmaphorum.com/webinars/oncology-treatment-decisions-arent-just-based-on-clinical-data/
The power of R&D collaborations to improve outcomes in rare diseases Share XThe power of R&D collaborations to improve outcomes in rare diseaseshttps://pharmaphorum.com/webinars/pharma-research-outcomes-rare-diseases/
Sales coaching: preparing for the new reality in pharmaCOVID-19 has been a catalyst for a huge amount of change across the pharmaceutical industry, acting as an Share XSales coaching: preparing for the new reality in pharmahttps://pharmaphorum.com/whitepapers/pharma-sales-coaching-new-reality/
Utilising content metrics to improve digital engagementPharma companies are producing and distributing more digital content than ever due to the pandemic, meaning the content Share XUtilising content metrics to improve digital engagementhttps://pharmaphorum.com/whitepapers/content-metrics-digital-engagement-veeva/
Transform patient experience with intelligent hyper-personalisationSince 2019, pharmaceutical companies have been speeding to integrate digital channels and processes into their marketing efforts and Share XTransform patient experience with intelligent hyper-personalisationhttps://pharmaphorum.com/whitepapers/patient-experience-personalisation-indegene/
The evolution of clinical trials: the pharmaphorum podcast Share XThe evolution of clinical trials: the pharmaphorum podcasthttps://pharmaphorum.com/video/the-evolution-of-clinical-trials/
Patient engagement processes: the pharmaphorum podcast Share XPatient engagement processes: the pharmaphorum podcasthttps://pharmaphorum.com/podcast/patient-engagement-processes/
Digital Innovators: Wellthy Therapeutics’ Abhishek Shah Share XDigital Innovators: Wellthy Therapeutics’ Abhishek Shahhttps://pharmaphorum.com/digital/digital-innovators-wellthy-therapeutics-abhishek-shah/
6 critical success factors of a successful rapid first commercial launch Share X6 critical success factors of a successful rapid first commercial launchhttps://pharmaphorum.com/partner-content/6-critical-success-factors-of-a-successful-rapid-first-commercial-launch/
How to innovate and influence people in times of misinformation Share XHow to innovate and influence people in times of misinformationhttps://pharmaphorum.com/partner-content/how-to-innovate-and-influence-people-in-times-of-misinformation/
Formedix Partnered with CDISC to Give Free Access to CDASH-Compliant eCRFs Share XFormedix Partnered with CDISC to Give Free Access to CDASH-Compliant eCRFshttps://pharmaphorum.com/partner-content/formedix-partnered-with-cdisc-to-give-free-access-to-cdash-compliant-ecrfs/
PRISYM ID Achieves Zebra Technologies Validation Share XPRISYM ID Achieves Zebra Technologies Validationhttps://pharmaphorum.com/partner-content/prisym-id-achieves-zebra-technologies-validation/
AXON appoints Colette Balaam as its new US Managing Partner Share XAXON appoints Colette Balaam as its new US Managing Partnerhttps://pharmaphorum.com/partner-content/axon-appoints-colette-balaam-as-its-new-us-managing-partner/
Prescient Healthcare Group to Partner with Bridgepoint Development Capital Share XPrescient Healthcare Group to Partner with Bridgepoint Development Capitalhttps://pharmaphorum.com/partner-content/prescient-healthcare-group-to-partner-with-bridgepoint-development-capital/
